Fig. 1

Change of biomarkers relative to baseline for all 3 treatment groups over time. Note: data for CTX-I are not presented at week 4 because patients did not fast prior to this sample collection. *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001 compared to placebo. P values are multiplicity adjusted across all potential pairwise comparisons in treatment by time using Tukey method